about
Physiopathology of intrauterine growth retardation: from classic data to metabolomics.Clinical metabolomics and nutrition: the new frontier in neonatology and pediatrics.Should we definitively abandon prophylaxis for patent ductus arteriosus in preterm new-borns?Nephrogenic syndrome of inappropriate antidiuresis: a novel cause of euvolemic hypotonic hyponatremia in newborns. Diagnosis and practical management.Ultrasonography and neonatal urinary tract infections.Renal safety of Non Steroidal Anti Inflammatory Drugs (NSAIDs) in the pharmacologic treatment of patent ductus arteriosus.Neonatal hyponatremia: differential diagnosis and treatment.Metabolomics in adult and pediatric nephrology.Metabolomics and fetal-neonatal nutrition: between "not enough" and "too much".C. luteola infection in paediatrics: description of a rare neonatal case and review of the literature.Myoinositol: a new marker of intrauterine growth restriction?New diagnostic possibilities in systemic neonatal infections: metabolomics.Metabolomics and the great obstetrical syndromes--GDM, PET, and IUGR.Metabolomics technology and their application to the study of the viral infection.Clinical impact of human breast milk metabolomics.The biomarkers of fetal growth in intrauterine growth retardation and large for gestational age cases: from adipocytokines to a metabolomic all-in-one tool.The choice of amniotic fluid in metabolomics for the monitoring of fetus health.Urine metabolomic profiling in neonatal nephrology.Isolated 'sign of the horns': a simple, pathognomonic, prenatal sonographic marker of Crisponi syndrome.Paracetamol in Patent Ductus Arteriosus Treatment: Efficacious and Safe?Monitoring neonatal fungal infection with metabolomics.A case of neonatal urosepsis with multifocal osteoarthritis: could ultrasonography change the clinical course?Ultrasound in developmental dysplasia of the hip: A screening study in Sardinian newbornsMetabolomics and Cardiology: Toward the Path of Perinatal Programming and Personalized MedicineMetabolomics in newborns with intrauterine growth retardation (IUGR): urine reveals markers of metabolic syndrome.Changes in urinary PGE2 after ibuprofen treatment in preterm infants with patent ductus arteriosus.Urinary (1)H-NMR and GC-MS metabolomics predicts early and late onset neonatal sepsis.Individualized fortification of breast milk in 41 Extremely Low Birth Weight (ELBW) preterm infants.Urinary metabolomics (GC-MS) reveals that low and high birth weight infants share elevated inositol concentrations at birth.Italia-Netherland PhD Program: the I.O. PhD Research Program.Is the body composition development in premature infants associated with a distinctive nuclear magnetic resonance metabolomic profiling of urine?Drug treatments in a neonatal setting: focus on the off-label use in the first month of life.PROM and Labour Effects on Urinary Metabolome: A Pilot Study.1H NMR-based urine metabolic profile of IUGR, LGA, and AGA newborns in the first week of lifeInvestigation of the1H-NMR based urine metabolomic profiles of IUGR, LGA and AGA newborns on the first day of lifeSoluble CD14 subtype (sCD14-ST) presepsin in critically ill preterm newborns: preliminary reference rangesUrinary 1H-NMR Metabolomics in the First Week of Life Can Anticipate BPD DiagnosisExposure to tobacco smoke and low birth weight: from epidemiology to metabolomics
P50
Q30571544-662C80BA-CD1C-450B-89C9-6A3D88B8791AQ34177558-0AC20A43-99FF-43CB-92A7-DDCDB92284B7Q35580251-51ED6ABE-AD38-4DC4-9BDD-C7A70D73C76DQ37635187-C10DAC67-F43A-4529-9BDA-EFF1E7952AB2Q37793064-AC31C93A-4359-4517-B6DC-50D7159FF9E4Q37937643-07027395-15A2-4B94-B87B-C5158C2000A4Q37937654-45EEC4E4-5FD5-421F-B0C3-86BED2E7A08AQ38101454-A4A4F3D1-37CC-4924-B3F1-1290C55890B2Q38144776-E59FCD32-968A-47D2-8C82-E54248613007Q38148874-0EC74C25-5ADD-4C2E-865A-A200630FD7B7Q38161981-3F14304B-847C-4C78-AFAD-CCBD4E052BA2Q38202767-43421A9E-344F-46AD-B03B-D14DD6F7743DQ38255760-64DE798D-3C07-43E8-995A-4CC81F49AC4AQ38256890-ED9A0D92-DEA9-4C29-9E2E-E5A5AF94079BQ38358739-ACFA71BB-FD04-4299-B792-595FED8463B8Q38406184-D962283E-6EF0-456B-AC23-83939EA25713Q38694550-A3CD4197-F45A-44FB-AD5E-93123FEAB90AQ39187138-A9130368-364C-4DA2-BEA5-A07FA003D221Q40294396-81450CBE-3D71-4AA6-A5AA-925D21A4356AQ41371050-7A9DD1E1-9A8C-488A-A0F4-1AC21F85A951Q41715648-7758AFDB-B6CC-4AFE-8428-8E4F302585CDQ41772668-2EE19DC2-4F33-4459-BC19-6307F0D03A0EQ42112024-4D227159-DD77-440B-8F9F-A787F46BE87DQ42333907-A612FDA7-95CC-48BE-BBF0-3C9AABF8972EQ44636391-159BFD59-990E-47D2-8F57-C9580E0F614FQ46219964-4A506B6B-6D3A-47E7-9F9E-B590463C4452Q46316924-3AB7ADBF-C51E-4DAF-9FA5-7945E9C177F0Q47390813-6A163D0F-1B12-4A00-845C-5151B64B0C34Q47432528-A271DA0A-5258-4BB1-B6CC-DA574361EA8CQ48925882-E79EF160-44B0-40F1-A8B2-4E0D12C93BE9Q50092123-01C93D17-5053-4230-93A4-4009A6AEF39EQ51785466-360406AE-EE1A-42CD-AF42-5471F5D4C288Q55315799-26A176DA-355E-4E43-A504-039762926FDAQ61702792-461E19CC-E1CF-4E32-A282-20A34C0AAA38Q61702796-B6A1F4F9-3424-43FC-86DE-567F0C42F7BEQ61702807-BFA51531-8A86-442D-80F5-433B88B0BA7EQ90538125-AFF7A4DB-18EF-44B6-8503-90000A3F6863Q90564867-8089641A-0FA4-4FE0-A6E1-3B2D310AF8ED
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Angelica Dessì
@ast
Angelica Dessì
@en
Angelica Dessì
@es
Angelica Dessì
@nl
type
label
Angelica Dessì
@ast
Angelica Dessì
@en
Angelica Dessì
@es
Angelica Dessì
@nl
prefLabel
Angelica Dessì
@ast
Angelica Dessì
@en
Angelica Dessì
@es
Angelica Dessì
@nl
P106
P1153
35344576700
P21
P31
P496
0000-0002-1154-2118